Keymed Biosciences *(2162.HK)*

2026 Interim Results

Aug 2026



Disclaimer

THIS DOCUMENT OR THE INFORMATION CONTAINED HEREIN IS NOT INTENDED TO AND DOES NOT CONSTITUTE ANY OFFER OR INVITATION, SOLICITATION, COMMITMENT OR ADVERTISEMENT OF ANY OFFER FOR SUBSCRIPTION, PURHCASE OR SALE OF ANY SECURITIES, NOR SHALL ANY PART OF THIS DOCUMENT FORM THE BASIS OF OR BE RELIED ON IN CONNECTION WITH ANY CONTRACT OR COMMITMENT WHATSOEVER.

This document contains strictly confidential and proprietary information in relation to Keymed Biosciences Inc. (the "Company") and is only being made available on a confidential basis for the exclusive use of the person to whom it is addressed (the "Recipient") and may not be reproduced or transmitted to any other person. The information contained in this document has not been independently verified by the Company and its controlling shareholders, directors, management, employees, agents, affiliated entities or persons, advisers or representatives (collectively, the "Representatives"). By accepting this document, you agree that you and your representatives will keep this document strictly confidential and must not use the information contained herein for any other purpose and must not communicate, reproduce, distribute or disclose it in any other manner to any other person, internally or externally, or refer to it publicly, in whole or in part. You and your representatives shall not cite this document, in whole or in part, at any time, in any manner or for any purpose without the prior written consent of the Company. If you are not the intended recipient of this document, please delete and destroy all copies immediately and do not copy or forward them to any other person.

No representation, express or implied, is made in respect of the fairness, reliability, completeness or accuracy of the information contained in this document, nor the reasonableness of any assumptions herein, and no party shall be entitled to rely on the fairness, reliability, completeness or accuracy of the information or any oral or written communication in connection with proposed investment in the Company ("Proposed Investment"), and the reasonableness of any assumptions herein. The information contained herein is subject to change without notice, and will not be updated to reflect any material development after the date of this document. Neither the Company nor the Representatives shall have any liability for any loss in connection with this document, the use of any of the information herein or any loss however arising in connection with this document. This document does not purport to contain all of the information that may be required by or otherwise important to the Recipient and the Recipient should conduct its own due diligence and independent analysis of the Company and the information contained or referred to herein.

This document may contain forward-looking statements. Such forward-looking statements are based on a number of assumptions in connection with the Company's operation and future development plan, market (financial and other aspects) conditions, industry and regulatory trends, and growth prospect. The validity of such assumptions are affected by a number of factors, both identified and unknown, and includes factors beyond the Company's control, and such factors may cause material deviations between the Company's actual performance to that expressed or implied in such forward-looking statement. You are cautioned not to place undue reliance on these forward-looking statements, as these statements are subject to risks both identified and unknown, involve inherent uncertainties and speaks only as of the date they are made. Neither the Company nor the Representatives shall be responsible updating the forward-looking statements in accordance with events or circumstances that occur after the date of this document.

This document has been prepared solely for information purposes and does not constitute a recommendation regarding any offer for subscription for the securities of the Company and does not constitute and should not be considered as any form of financial or investment opinion or recommendation by the Company or the Representatives.

Nothing in this document should be construed as regulatory, valuation, legal, tax, accounting or investment advice and it does not constitute a recommendation, solicitation, offer or commitment to purchase, sell or underwrite any securities from you, to you, or on your behalf, or to extend any credit or provide any insurance to you or to enter into any transaction. Unless otherwise agreed in writing, any third party from whom you receive this document is not acting as your financial adviser or fiduciary. Before you enter into any transaction, you should ensure that you fully understand the potential risks and rewards of that transaction and you should consult with such advisers as you deem necessary to assist you in making these determinations, including, but not limited to, your accountants, investment advisers and legal and/or tax experts.

If you do not accept the forgoing conditions or any confirmations and representations contained herein, please immediately return this document to the Company.

Contents

01 Highlights in H1 2026

03 R&D Progress in H1 2026

03 Company overview

04 Kangyueda(康悦达®, Stapokibart) introduction



Key milestones of Keymed Bio in H1 2026

Realizing commercial value, accelerating revenue, deepening potential pipelines, ample cash reserves

康悦达®
rapid commercialization
NEML inclusion

- In H1 2026, Kangyueda (康悦达®) sales amounted to **393M**, YOY**+132%**↑
- Commercial coverage (as of June 30, 2026)，team: **~500** members, divided into dermatology and rhinology divisions; Coverage includes **>1600** hospitals (more than 1000 approved for in-hospital use) and over **670+** pharmacies
- NRDL Inclusion: **3** indications (**adult moderate-to-severe AD, CRSwNP, SAR**), effective Jan 1, 2026
- Included in the National Essential Medicines List (2026 Edition), effective from Sep 1, 2026

Outstanding financial performance and abundant cash

- In H1 2026, BD-related revenue: **224M**, milestone payments for the CMG901
- In 2026 H1 ,the net profit achieved **1.2B**, mainly due to the disposal of the equity of Ouro Medicines, achieving a gain of **1.68B**
- **Cash position : RMB 3.24B (as of Jun 30, 2026) vs 1.96 billion (as of Dec 31, 2025)** (incl. short-term bank wealth management products)

R&D progress

- **CMG901/ AZD0901（Claudin 18.2 ADC）: the first MRCT Ph3** for 2L+ GC/ AEG achieved positive topline results, and the OS demonstrated statistically significant and highly clinically meaningful benefits
- **CM336（BCMA/CD3 BsAb):** With Gilead's support, auto-immune disease indication is leading globally
- **CM512 (TSLPxIL-13 BsAb):** Ph2 of CRSwNP has achieved all endpoints: rapid onset, one injection maintained for half a year, and the incidence of ADA is extremely low. The indications for Asthma, COPD, CSU，AD, etc. are advancing rapidly

Note: All amounts are in RMB units. Minor discrepancies due to rounding may exist, please refer to the annual results announcement for exact figures


Commercialization and financial highlights in H1 2026




H1 2026 Financials: Robust Results from Commercial Scale-up & NewCo Closed-Loop, Ample Cash

- H1 2026 operating revenue: 616M. **Pharmaceutical sales (~393M, YoY +132%)** all from Kangyueda®; **partnership revenue (~223M)** chiefly from CMG901 R&D milestones.
- **R&D, G&A and finance expenses** edged down YoY, reflecting solid cost control. **Selling expenses** stood at 219M, with Kangyueda® revenue covering both selling expenses and production costs.
- **Net profit: 1.22B**, largely from a **1.68B** gain on disposal of Ouro Medicines equity.
- **Cash on hand** (incl. short-term bank WMPs): **3.24B** on Jun 30, 2026, versus 1.96B on Dec 31, 2025.

Revenue: Fast volume growth, BD-driven revenue (RMB 100mn)



Operating Expenses & Fixed-asset CapEx (RMB 100mn)



Note: **All amounts are in RMB units.** Minor discrepancies due to rounding may exist, please refer to the annual results announcement for exact figures

Significant profit in H1 2026, achieving a net profit of RMB 1.2B

（RMB'000）	1H 2026	1H 2025
Revenue	617,068	498,752
Cost of sales	-118,743	-33,476
Gross profits	498,325	465,276
Other income and gains (NB1)	1,705,973	75,543
R&D expenses	-338,749	-360,018
Administrative expenses	-85,551	-89,259
Selling and distribution expenses (NB2)	-218,387	-137,577
Other expenses (NB3)	-47,066	-21,600
Finance costs (NB4)	-6,377	-7,463
Share of loss of a joint venture	-401	-566
Income tax expense(NB5)	-290,154	-3,135
Net Profit / (Loss)	**1,217,613**	**-78,799**

NB1: Other income mainly includes:

① RMB 1.68B gain on fair-value movement of Ouro Medicines equity (disposed in-period);

② Government grants: RMB 37,644k;

③ Interest & WMP income: RMB 22,941k;

④ CDMO service revenue: RMB 4,205k.

NB2: Selling expenses: mainly commercial-team compensation, academic conferences and marketing costs.

NB3: Other expenses: net foreign exchange loss of RMB 34,800k.

NB4: Finance expenses: primarily interest on bank borrowings.

NB5: Income tax expenses mainly comprise:

① Profits tax accrued by Hong Kong subsidiary (from Ouro Medicines equity disposal gain);

② 10% US withholding tax accrued for CMG901 milestone payments, reversible upon successful prior-period with holding tax refund.

First full fiscal year of commercialization: multi-dimensional strategies to accelerate sales ramp-up of Kangyueda (康悦达®)

1 Focusing on immune diseases, building a professional sales team for dermatology and rhinology

- **3 Approved Indications:** Moderate-to-Severe AD in Adults, CRSwNP, SAR (Exclusive)
- **Precision Marketing:** Segmented into dermatology and rhinology fields
- **Continuous Expansion of Commercial Team:** As of June 30, 2026, ~500 members



2 Expand channels & market access, accelerate penetration in high-potential regions and hospitals

- As of Jun 30, 2026: coverage across **30 provinces and 280+ cities**
- Over **1,600** covered hospitals; **1,600** hospitals with consistent prescription output; more than **1,000** hospitals for in-hospital drug administration
- Commercial channels: stable partnerships with 57 primary distributors, with presence in **670+ pharmacies**
- **Medical Insurance (NRDL):** 3 indications of 康悦达® and the prefilled autoinjector included
- **National Essential Medicines List:** Included in the National Essential Medicines List (2026 Edition), effective Sep 1, 2026.





R&D Progress in H1 2026



R&D progress in H1 2026: focus on autoimmune, chronic diseases and oncology

Approved

Kangyueda(康悦达®)
Stapokibart
IL-4Rα（1st domestically）

Moderate-to-severe AD
The 1st domestic biologic, forge the EASI-90 new era

CRSwNP
First in China, Ushering in a New Era of Biologic Therapy

SAR
The World's Exclusive Solution, Revolutionizing the Treatment Landscape of the Disease

Ph III

Stapokibart
IL-4Rα（1st domestically）

- Adolescent AD（BLA）
- Prurigo Nodularis（BLA）
- Pediatric AD
- Adolescent SAR

AstraZeneca
CMG901
CLDN18.2 ADC

- 2L+CLDN18.2+ GC/ AEG
- 1L CLDN18.2+/HER2- GC/EGJ/EAC

CM336
BCMA/CD3 BsAb

- 2L+RRMM (with CM313)
- Light Chain Amyloidosis

Ph II

AstraZeneca
CMG901
CLDN18.2 ADC

- perioperative treatment of AEG
- 2L+BTC、1L PDAC

CM512
Long-acting TSLP×IL13 BsAb

- CRSwNP
- COPD
- Asthma
- AD

CM313
CD38 antibody

- IgAN

Ph I

Belenos
CM512
Long-acting TSLP×IL13 BsAb

GILEAD Lakefront biotherapeutics
CM336（oversee）
BCMA/CD3 BsAb

CM383 Aβ protofibrils antibody

CM559 N3pG-Aβ antibody

- Alzheimer's Disease

CM518D1
CDH17 ADC

- Colorectal Cancer

Note: Only key clinical pipeline items are listed. For a comprehensive clinical pipeline, please refer to Part 2: Company Overview – Clinical Pipeline.

AD: Atopic Dermatitis; BLA: Biologics License Application; GC: Gastric Cancer; AEG: Adenocarcinoma of the Esophagogastric Junction; EAC: Esophageal Adenocarcinoma; RRMM: Relapsed/Refractory Multiple Myeloma

Autoimmune & Chronic Diseases Oncology

BD asset updates: AstraZeneca accelerates MRCT for CLDN18.2 ADC

AstraZeneca

- In Feb 2023: Keymed entered into a global exclusive license agreement with AZ. AZ is responsible for global R&D, manufacturing, and commercialization of CMG901. The total transaction value exceeds USD 1.1 B, plus tiered royalties up to low double digits.
- At the end of July 2026, the first global Ph3 (CLARITY Gastric01, 2L+ CLDN18.2+ GC/ AEG) achieved positive topline results. Overall survival (OS) demonstrated statistically significant and highly clinically meaningful benefits (the proportion of CLDN18.2 expression in enrolled patients was ≥ 25%).
- AZ estimates the peak sales of CMG901/ AZD0901 to be USD 3 ~5 B

Indication	Clinical Stage	Expected enrollment	Expected Milestones	
2L+ CLDN18.2+ GC/ AEG	Ph 3	572	Global BLA: 2026 Q4	CDE BTD、EMA ODD FDA FTD&ODD
1L CLDN18.2+ HER2- GC/AEG/EAC (Combination Therapy)	Ph 3	2130 (426 in China)	**FPI: Feb 2026,** triggered a $45 million milestone payment	Fastest development progress worldwide
CLDN18.2+Solid Tumors (3 Cohorts: GC, 1L PDAC, 2L+BTC)	Ph 2	224	enrollment completed	
perioperative treatment of AEG (Combination Therapy)	Ph 2	Total 100	initiated in July 2025	

GC: Gastric Cancer; AEG: Adenocarcinoma of the Esophagogastric Junction; EAC: Esophageal Adenocarcinoma

Note: all clinical pipelines listed above are being advanced by partners within their licensed regions. For the same indication, only the highest clinical stage is shown. Data sourced from respective company websites or clinicaltrials.gov.

CM336：Accelerating overseas clinical development, continuously expanding new indications

Global Collaboration & Development Milestones

2024.11

康诺亚 Keymed Biosciences × OURO MEDICINES

CM336（BCMA/CD3 BsAb）
Global Rights Outside Greater China

Received $16 million upfront payment

Plus Ouro minority equity + up to $610 million milestone payments + tiered royalties on net sales

2026.03

GILEAD Lakefront biotherapeutics × OURO MEDICINES

Gilead / Lakefront Acquired Ouro Medicines

Received $257 million upfront payment

Subsequent milestones and tiered royalties continue

2027E

Clinical Advancement & Indication Expansion

Expected to initiate pivotal registrational clinical trials for AIHA and ITP in 2027

US$273m+

Confirmed Upfront Cash

AIHA ITP
FDA FTD and ODD

Indication Landscape & Clinical Progress: Dozens of Potential Expandable Indications

Hematology	**Rheumatology**	Dermatology	Neurology	Renal/Transplant
AIHA	SjD	BP	MG	IgAN
ITP	IIM	PV	CIDP	PMN
APS	RA	DM	NMOSD	AMR
FNAIT	SLE	CLE	MS	DSAs

Clinical Development


- Ph Ib/IIa
- IIT
- Clinical Study Planning

Notes:AIHA: Autoimmune Hemolytic Anemia; ITP: Immune Thrombocytopenia; APS: Antiphospholipid Syndrome; FNAIT: Fetal and Neonatal Alloimmune Thrombocytopenia; SJD: Sjögren's Disease; IIM: Idiopathic Inflammatory Myopathy; RA: Rheumatoid Arthritis; SLE: Systemic Lupus Erythematosus; BP: Bullous Pemphigoid; PV: Pemphigus Vulgaris; DM: Dermatomyositis; CLE: Cutaneous Lupus Erythematosus; MG: Myasthenia Gravis; CIDP: Chronic Inflammatory Demyelinating Polyneuropathy; NMOSD: Neuromyelitis Optica Spectrum Disorder; MS: Multiple Sclerosis; IgAN: IgA Nephropathy; PMN: Primary Membranous Nephropathy; AMR: Antibody-Mediated Rejection; DSAs: Donor-Specific Antibodies; IIT: Investigator-Initiated Trial

CM336 – key domestic registrational trials launched; advancing oncology & autoimmune indications

layout in oncology and autoimmune diseases


- Administered by SC, suitable for various clinical application scenarios of various diseases.
- 2L+RRMM: Ph3 ongoing.
- Light Chain Amyloidosis: Ph2 enrollment accelerating; BLA submission expected in **2027H2**.
- Autoimmune pipeline advancing rapidly.



excellent clinical performance

✓ **MM:** In Ph2 dose-expansion cohort, only 4.7% of subjects experienced Grade 2 CRS; no ICANS. Target dose: ORR 95.2%, ≥CR 81%, 12-month PFS 82.5%. Potential BIC.

✓ **AIHA:** In 2 patients with prior multiple treatments, no CRS or ICANS. Hemoglobin levels returned to normal in 1 patient by Day 17, and 1 patient achieved CR by Day 21. **Results published in NEJM.**




The NEW ENGLAND JOURNAL of MEDICINE

CURRENT ISSUE SPECIALTIES TOPICS

CORRESPONDENCE

BCMA-Targeted T-Cell Engager for Autoimmune Hemolytic Anemia after CD19 CAR T-Cell Therapy

Published June 11, 2025 | N Engl J Med 2025;392:2282-2284 | DOI: 10.1056/NEJMc2502297 | VOL. 392 NO. 22

Copyright © 2025

MM data as of: May 2026; AIHA data sourced from NEJM

AIC: Autoimmune Hematological Disorders: Includes autoimmune hemolytic anemia (AIHA) and immune thrombocytopenia (ITP)； SAI: Seropositive Autoimmune Diseases; AIBD : Autoimmune Bullous Diseases

ORR: Objective Response Rate; CR: Complete Response; MRD: Minimal Residual Disease; PFS: Progression-Free Survival

CM313 – anti-CD38 monoclonal antibody，potential BIC treatment for IgAN


Disease-area portfolio & clinical progress

- Ph2 IgAN study advancing rapidly; Ph3 initiation expected in 2027.
- Ph 1/2 RRMM progressing rapidly; subsequent Ph3 trial in 2L+ RRMM will be conducted in combination with CM336 (BCMA/CD3).

Drug	Indications	Clinical stage: Ph 1	Ph 2	Ph 3
CM313 CD38 Antibody	IgAN			
	RRMM			
	2L+ RRMM（in combo with CM336 BCMA/CD3 BsAb			

BIC potential clinical data for IgAN

- Preliminary Ph2 IgAN data: once-monthly dosing
- Greater reduction in 24h-UPCR vs marketed products for the same indication.



CM313 IgAN DCO: 20260716，Preliminary data;
No head-to-head comparisons across products.

CM512 – The world's first long-acting TSLP x IL-13 dual blocker

TSLP x IL-13 BsAb: advantages & highlights

- **World's first IgG-like long-acting TSLP x IL-13 BsAb**: Inhibits TSLP-induced early inflammation and blocks IL-13-driven skin and respiratory pathology.
- Half-life up to **70 days** (superior to similar products such as Lunsekimig ≈10 days).
- **Low immunogenicity**, better long-term dosing safety

Ph I clinical study demonstrates favorable safety and tolerability

- Healthy Subjects (n=64): Single and multiple ascending doses showed **good safety and tolerability.** No TEAEs met criteria for dose-limiting toxicity; no SAEs were reported.
- Moderate-to-severe AD Patients (n=46): The overall incidence of TEAEs and SAEs was comparable to the placebo group.

Ph I clinical study results indicate rapid, durable, and stable efficacy

- Multiple Type 2 inflammatory biomarkers significantly reduced.
- CM512 delivers rapid, durable stable disease control in moderate-to-severe AD patients:
  - Week 6: **50%** EASI-75 in 300mg group (proposed clinical dose) vs. 7% in placebo.
  - Week 12: EASI-75 **58.3%** and EASI-90 **41.7%** in 300 mg group vs. 21.4% and 0% in placebo.

CM512 – the world's first long-acting TSLP/IL-13 BsAb achieved all endpoints in Ph2 clinical trial

Shrinks nasal polyps rapidly and significantly relieves nasal congestion in **~4 weeks** after dosing

One dose, **6-month** sustained efficacy: significantly greater reduction from baseline in Nasal Polyp Score (NPS) at Week 24 vs. control


Zero serious adverse events with CM512 during treatment; anti-drug antibody (ADA) incidence was extremely low.

Supported by these Phase 2 findings, the Company is accelerating initiation of the Phase 3 trial for CM512 injection in CRSwNP, with 300 mg Q24W selected as the dosing regimen.

indication	Clinical stage	Expected enrollment	Expected Progress
CRSwNP BTD from CDE	Ph 2	120	completed
	Ph 3	236	Initiated in 2026H2
Moderate-to-severe Asthma	Ph 2	200	enrollment completed at the end of 2026
Moderate-to-severe COPD	Ph 2	204	enrollment completed at the end of 2026
Moderate-to-severe adult AD	Ph 2	200	enrollment
CSU	Ph 2	48	enrollment completed in 2027

CM518D1 – A global leading CDH17 ADC molecule with potential BIC profile

Independently Developed CDH17 ADC



The next blockbuster ADC target:

- **Clear membrane protein localization**
- **Favorable internalization properties**
- **High specificity**

Potential BIC Molecule for Treating Gastrointestinal Tumors

CM518D1 utilizes a cleavable linker + Topoisomerase I inhibitor, DAR=8

Topoisomerase I Inhibitor Advantages:

- **Stronger cell membrane permeability**
- **Significant bystander effect**
- **Wider dosing window**

Excellent Preclinical Data

- Superior efficacy: effective dose **<1 mg/kg** in gastric/pancreatic cancer models.
- Safety: HNSTD 30 mg/kg, **safety window >30-fold**, positioning it as a potential Best-in-Class.

Clinical Progress

- June 2025: Initiated Phase I/II trial in advanced solid tumors (planned enrollment: 434 patients). Ph I data will be presented at the ESMO.
- July 2025: received FDA clinical trial approval.

Key expected milestones for R&D in 2H2026 and 1H2027

	2H2026	1H2027
Stapokibart IL-4Rα		New indication approval • Moderate-to-severe AD in adolescents • Prurigo Nodularis
CMG901 **CLDN18.2 ADC** AstraZeneca	2L+ CLDN18.2+ GC/ AEG • MRCT Ph III Data readout • Multi-country BLA	
CM512 **TSLP×IL13 BsAb** Belenos	√ China Ph2 data readout、 Phase3 initiation： CRSwNP • US PhIb data readout: Asthma • China Ph2 enrollment completed： Asthma、COPD	• Overseas Ph3 initiation： CRSwNP • China Ph3 initiation： Asthma 、COPD
CM336 **BCMA/CD3 BsAb**	• RRMM Ph2 clinical data、PV& Light chain amyloidosis IIT data paper published	• Global pivotal trial initiation： ITP、AIHA • New indications global POC Ph2a initiation
CM313 CD38 antibody	• Ph2 trial enrollment completed : IgAN	• Ph3 initiation: IgAN
CM518D1 CDH17 ADC	• China Ph I data presented at ESMO Congress: solid tumors	
IND plans	√ CM529D1 DLL3 /SEZ6 BsAb ADC SCLC √ CM583 Long-acting CGRP/PACAP BsAb Migraine √ CM551 Long-acting TL1-A/IL-23p19 BsAb IBD • ……	• siRNA、PROTAC、Bispecific ADCs 、Brain-penetrant Bispecific Antibody

BLA: Biologics License Application； IND: Investigational New Drug (Application)； AD: Atopic Dermatitis； CRSwNP: Chronic Rhinosinusitis with Nasal Polyps； GC: Gastric Cancer; AEG: Adenocarcinoma of the Esophagogastric Junction； EAC: Esophageal Adenocarcinoma； COPD: chronic obstructive pulmonary disease; RRMM: Relapsed/Refractory Multiple Myeloma；

Target for 2027: 2 marketed products， 10 plus pivotal registration trials

Expected approved for market launch

Kangyueda(康悦达®)
Stapokibart
IL-4Rα（1st domestically）

- **Moderate-to-severe AD**
  The 1st domestic biologic，forge the EASI-90 new era
- **CRSwNP**
  First in China, Ushering in a New Era of Biologic Therapy
- **SAR**
  The World's Exclusive Solution, Revolutionizing the Treatment Landscape of the Disease
- **Adolescent AD**
- **Prurigo Nodularis**

AstraZeneca
CMG901
CLDN18.2 ADC

2L+CLDN18.2+ GC/ AEG (global)

Expected to conduct pivotal registration trials

CM512
Long-acting
TSLP×IL13 BsAb

- CRSwNP (conduct in China and US)
- Asthma
- COPD
- ……

AstraZeneca
CMG901
CLDN18.2 ADC

- 1L CLDN18.2+ HER2- GC/AEG/EAC
- 2L+ Biliary Tract Cancer(BTC)

CM313
CD38 antibody

- IgAN

GILEAD Lakefront biotherapeutics
CM336
BCMA/CD3 BsAb

- AIC：AIHA and primary ITP
- Light Chain Amyloidosis (China)
- BCMA/CD3+CD38 2L+ RRMM (China)

Autoimmune & Chronic Diseases
Oncology

AD: Atopic Dermatitis; CRSwNP：Chronic Rhinosinusitis with Nasal Polyps；SAR：Seasonal Allergic Rhinitis；COPD：Chronic Obstructive Pulmonary Disease；GC: Gastric Cancer; AEG: Adenocarcinoma of the Esophagogastric Junction; EAC: Esophageal Adenocarcinoma; MM: Multiple Myeloma

Sustainable Commercial Product Matrix: Upgrading from "Single-Product Growth" to "Portfolio-Driven Growth"

Keymed Biosciences | 2016-2026 KEYMED 10th

Approved | Stapokibart: Adult AD、CRSwNP、SAR

Oncology Autoimmune or Chronic Disease

Approved in China Overseas Approval

	2027E	2028E	2029E	2030
Stapokibart Kangyueda 康悦达® IL-4Rα antibody	Adult AD CRSwNP SAR Adolescent AD PN	Adult AD CRSwNP SAR Adolescent AD PN Pediatric AD	Adult AD CRSwNP SAR Adolescent AD PN Pediatric AD Adolescent SAR	Adult AD CRSwNP SAR Adolescent AD PN Pediatric AD Adolescent SAR
CM512 TSLP/IL-13 BsAb			CRSwNP	CRSwNP Asthma
CM313 CD38 Antibody				IgAN
CM336 BCMA/CD3 BsAb		AL	AL ITP PV	AL ITP AIHA PV 2L+RRMM
CMG901 CLDN18.2 ADC	2L+GC/AEG	2L+ GC/AEG 2L+ BTC	2L+ GC/AEG 2L+ BTC	2L+GC/AEG 2L+ BTC 1L GC/AEG/EAC

Note： *AD: Atopic Dermatitis; CRSwNP：Chronic Rhinosinusitis with Nasal Polyps；SAR：Seasonal Allergic Rhinitis；* GC: Gastric Cancer; AEG: Adenocarcinoma of the Esophagogastric Junction; EAC: Esophageal Adenocarcinoma*; AIC:autoimmune cytopenias; AIHA :autoimmune hemolytic anemia; ITP: immune thrombocytopenia; PV: pemphigus vulgaris ； RRMM: Relapsed/Refractory Multiple Myeloma.*

Company overview



Keymed Bio company overview

A comprehensive biopharma dedicated to addressing significant unmet medical needs through diversified technology platforms

Robust Clinical Pipelines

Continuously providing innovative solutions for disease areas with significant unmet needs.

- **1** approved product**,** **3** Indications
- **12+** assets in clinical development
- **50+** assets in preclinical development

Comprehensive R&D Capabilities

- Proven end-to-end experience in innovative drug R&D and commercialization
- Platforms include: antibodies, ADCs, oligonucleotides, small molecules (e.g., PROTACs), and blood-brain barrier (BBB) Penetrating Antibody Delivery Platform
- Strong clinical development capabilities

Proprietary Commercialization Capabilities

- Fully integrated, self-built commercialization system covering the entire value chain
- Deep focus on therapeutic areas such as **Dermatology** and **Rhinology**

In-house Manufacturing Capabilities

Production capabilities compliant with FDA and NMPA cGMP requirements

- Total capacity now: **21,800L**
- New capacity: **24,000L** stainless steel production line process validation is currently underway
- Future planned capacity exceeds **100,000L**

Expanding talent pool to support long-term growth and commercialization needs

Actively advancing the commercial sales of Kangyueda (康悦达®) and R&D work for additional pipeline assets.

As of June 30, 2026

1768
Full-time Employees

131
Administration & Back-office Support

420
Drug R&D & Clinical Operations

722
CMC & Manufacturing

495
Commercial Team





In addition to our Chengdu headquarters, we have established offices in Shanghai, Beijing, Nanjing, Wuhan, Guangzhou, and other locations.

Diversified innovative technology platforms, with the best molecular modality, addressing unmet medical needs

Diversified innovative technology platforms empowering drug R&D with 50+ assets in pipeline

Antibodies Platform

- integrated R&D process and independent innovation capability

Small Molecule Platform

- PROTAC molecules with potent degradation activity
- Candidate molecules with high potency, stability, favorable pk and bioavailability

KeyMedSTAR™ ADCPlatform

- Proprietary novel toxin and linker platform: superior bystander killing effect and wide therapeutic window
- Proprietary GMP manufacturing facilities

VESIR™ Oligonucleotide Platform

- Innovative Chemical Modifications
- Liver-Targeting and Extrahepatic Delivery
- AI-Assisted Design, High-Throughput Oligonucleotide Synthesis and Screening


nTCE Bispecific Antibodies Platform

- High specificity and potent mechanism of action
- Research published in NEJM

KeyCND™ BBB-Penetrating Antibody Delivery Platform


- Targeting Alzheimer's Disease and various neurological disorders
- Targeted delivery of macromolecules, nucleic acids, and small molecules

KeyCND™: BBB-Penetrating Antibody Delivery Platform




TfR-Targeted Antibody Delivery

- ✓ Rapid brain entry, with a 20-fold increase in brain uptake
- ✓Drug distribution across the entire brain
- ✓Enhanced efficacy
- ✓Favorable safety profile
- ✓Subcutaneous injection, convenient and fast



TfR-Targeted siRNA Delivery

- ✓115-fold increase in brain siRNA exposure
- ✓Highly efficient neuronal endocytosis
- ✓No risk of anemia or infusion-related reactions (IRR)
- ✓Subcutaneous injection, convenient and fast



CD98hc-Targeted Antibody Delivery

- ✓Rapid brain entry with sustained exposure, 77-fold increase in brain uptake
- ✓Enhanced Aβ plaque clearance
- ✓No risk of anemia or IRR
- ✓Subcutaneous injection, convenient and fast

Keymed leverages the KeyCND™ platform to achieve multimodal brain-targeted drug delivery, dedicated to the R&D of therapies for CNS diseases.


Clinical Pipeline: 12 candidates in clinical trials, leading in the R&D process

Keymed Biosciences | 2016-2026 KEYMED 10th

Autoimmune or Chronic disease

	Pre-Clinical	IND	Ph-I	Ph-II	Ph-III	NDA	Launched	Partner	Keymed Rights
康悦达® 司普奇拜单抗 Stapokibart CM310 ★ IL-4Rα (mAb)	Moderate-to-severe AD--Adults					BTD granted by CDE / Priority Review / NDA approval in Sep,2024			Global
	Moderate-to-severe AD--Adolescents								
	Moderate-to-severe AD--Children								
	CRSwNP					Priority Review / NDA approval in Dec,2024			
	SAR					NDA approval in Feb,2025			
	Prurigo Nodularis								
	SAR--Adolescents								
CM512 TSLPxIL-13 (Bispecific) ★	CRSwNP			BTD granted by CDE				Belenos	Greater China
	Asthma								
	COPD								
	Moderate-to-severe AD								
	Chronic Spontaneous Urticaria(CSU)								
CM326 TSLP (mAb)	Asthma, CRSwNP, etc.							CSPC 石药集团	Global ex mainland China
CM336 BCMAxCD3 (Bispecific)	light chain amyloidosis(AL)			BTD granted by CDE				OURO MEDICINES, GILEAD, Lakefront biotherapeutics	Greater China
	autoimmune cytopenias(AIC)			FDT&ODD					
	SAI(SjD,IIM)								
	BP,PV								
CM313 CD38 (mAb)	IgAN							TIMBERLYNE THERAPEUTICS	Greater China
CM355/PRO-203 CD20/CD3 (Bispecific)	Systemic Sclerosis (SSc)							Prolium	
CM383 Aβ protofibrils (mAb)	Alzheimer's Disease								Global
CM559 N3pG-Aβ (mAb)	Alzheimer's Disease								Global

Clinical Pipeline: 12 candidates in clinical trials, leading in the R&D process



Cumulative R&D investment exceeds RMB 2.6 billion

51 Clinical trial approvals obtained for China class 1 new drugs

311 invention patent applications filed

AD: Atopic Dermatitis; CRSwNP: Chronic Rhinosinusitis with Nasal Polyps; GC: Gastric Cancer; AEG: Adenocarcinoma of the Esophagogastric Junction; EAC: Esophageal Adenocarcinoma; COPD: chronic obstructive pulmonary disease; RRMM: Relapsed/Refractory Multiple Myeloma

Large-scale commercial manufacturing system, cost advantages creating a commercial barrier

- The first-stage project involved a fixed asset investment exceeding **RMB 800 million**
- **High yield: 5-10 g/L**
- **Cost Efficiency**



- Total Capacity now: **21,800L**

3 pilot production lines and 3 commercial production lines

- New Capacity: **24,000L**

stainless steel production line process validation is currently underway （as below）

- Future capacity Planning **100,000L**

supporting commercial production for 5-15 antibody drugs.



Quality System Compliant with US, China, and EU cGMP Standards

- **World-class advanced technology, ranked #1 in Western China**




Kangyueda (康悦达®, Stapokibart) introduction



Keymed Bio : A Leader in immunological diseases with significant blue-ocean market potential

- Depending on the site of inflammation, dysregulation of the Type 2 immune pathway can manifest as various allergic diseases, including dermatological, respiratory, gastrointestinal, and cardiovascular conditions. **A single drug candidate holds the potential for multiple indications (Pipeline-in-a-Product).**
- Chinese epidemiological data indicates an adult prevalence of AD at 4.6% and 13% for children aged 1-7, with a total AD patient population exceeding 70 million. The patient populations for Allergic Rhinitis, Food Allergy, COPD, Asthma, and CRSwNP in China reach 250 million, 112 million, 100 million, over 60 million, and 38 million, respectively.



Data Sources: WHO, Expert Consensus, Diagnosis and Treatment Guidelines, Literature, etc.

First-in-China, Second-in-Global, potential Best-in-Class IL-4Rα antibody

Kangyueda (康悦达®) , Stapokibart，CM310 (IL-4Rα)



Moderate-to-severe AD
(Approved in Sept 2024)

CRSwNP
(Approved in Dec 2024)

SAR
(Approved in Jan 2025)

Adolescent AD
(BLA)

Prurigo Nodularis
(BLA)

Pediatric AD
(Ph Ⅲ)

Adolescent SAR
(Ph Ⅲ)

多项第1

- ✓ **1st domestically produced biologic** for treating moderate-to-severe AD

  Fills the gap in clinical trial data regarding higher treatment goals in the AD field.

- ✓ **1st biologic in China** for treating CRSwNP
- ✓ **1st IL-4Rα antibody drug globally** for treating SAR
- ✓ **1st in China and 2nd Globally** approved self-developed IL-4Rα antibody drug

Academic Publications

- ✓ Phase III clinical study results for SAR published in **Nature Medicine** (IF=58.7).
- ✓ Phase III clinical study results for CRSwNP published in **JAMA** (IF=55).
- ✓ Phase III clinical study results for Moderate-to-severe AD in adults published in **Allergy** (IF=12.6).

Regulatory Designations

- ✓ **Granted Breakthrough Therapy Designation by CDE**
- ✓ **Included in the Priority Review and Approval Program**

Kangyueda (康悦达®) | AD：The 1st domestic biologic，forging the EASI-90 era


- In the Ph III clinical study of Stapokibart for the treatment of AD, 500 subjects were randomized 1:1 to receive dosing Q2W for 16 weeks (double-blind treatment period). Subsequently, all subjects received Stapokibart treatment for 36 weeks (maintenance treatment period).
- Monotherapy with the first dose of Stapokibart rapidly relieved pruritus (itching) symptoms within 1 day; after 2 weeks of treatment, it demonstrated potent improvement in skin lesions across all body areas.

Fast-acting from the first dose

Rapid pruritus relief within 24 hours after the first dose[1]

Day1

The rate of change of daily PP-NRS from the baseline




*：司普奇拜单抗组显著优于安慰剂组，p=0.0006

Comprehensive improvement of skin lesions following the first dose[2]

2W

The rate of change in EASI at different sites from the baseline



*：司普奇拜单抗组显著优于安慰剂组，p<0.0001

1. Jianzhong Zhang,et al. 2024EADV, P0475.
2. Yan Zhao, et al. Int J Dermatol. 2025 May 2. doi: 10.1111/ijd.17820.


Kangyueda (康悦达®)｜AD：The 1st domestic biologic， forging the EASI-90 era

- **Dual primary endpoints and all secondary efficacy endpoints were met in the Phase III clinical study.** At Week 16, the EASI-75 response rate (≥75% improvement from baseline in Eczema Area and Severity Index) reached **66.9%**, and the IGA response rate (score of 0 or 1 with ≥2-point improvement from baseline) reached **44.2%**.
- After 52 weeks of treatment, **dual "9" efficacy** was achievable, with an EASI-75 response rate of **92.5%** and an EASI-90 response rate (≥90% improvement from baseline) of **77.1%**.

Potent response, Durable remission


16W

Comparison of Phase III Primary Endpoint Data for Stapokibart in the Treatment of AD (Non-Head-to-Head, **16-Week** Treatment)



52W

Comparison of **52-Week** Clinical Data for Stapokibart in the Treatment of AD (Non-Head-to-Head) [1,2]




1. Yan Zhao,et al. Allergy. 2025 May;80(5):1348-1357.
2. Andrew Blauvelt,et al. Lancet. 2017 Jun 10;389(10086):2287-2303.


Kangyueda (康悦达®)｜AD：The 1st domestic biologic， forging the EASI-90 era

➢ **Stapokibart demonstrated a favorable safety and tolerability profile.** Compared to Dupilumab—a widely used agent with the same indication and target—Stapokibart effectively reduces the risk of recurrence while maintaining excellent safety and tolerability. The recurrence rate was only **0.9%** after 52 weeks of treatment and remained at **0.9%** even 8 weeks post-discontinuation. The incidence of conjunctivitis was low at **5.3%**.


Lower Recurrence Rate and Favorable Safety Profile

Safety Data Comparison of Stapokihart (Phase III，Non-Head-to-Head) in AD






Recurrence Rate Comparison of Stapokihart (Phase III，Non-Head-to-Head) in AD



ADA：Anti-drug Antibody
Nab：Neutralizing Antibody
Recurrence: Subjects who achieved EASI-75 and IGA 0/1 at Week 16 of treatment had a <50% reduction in EASI score from baseline and an IGA score ≥2 at a certain follow-up visit during the maintenance phase.

Stapokibart | Phase III clinical data in adolescent AD： The EASI-75 response rate reached 73.9% at 18W

- In September 2025, pivotal Phase III clinical data for Stapokibart in adolescent AD were prominently featured at the 34th Congress of the EADV.
- **All Primary Endpoints Met (Week 18):** Stapokibart Significantly Improved Skin Lesions and Pruritus in Adolescent Patients
- **EASI-75 Response Rate:** In the Stapokibart group (n=120), **73.9%** of patients achieved an EASI-75 response, significantly higher than the placebo group (43.3%, P<0.0001). (Figure A)
- **IGA Response Rate:** The IGA response rate in the Stapokibart group reached **57.1%**, significantly superior to the placebo group (25.0%, P<0.0001). (Figure B)
- **PP-NRS Improvement:** At Week 18 of Stapokibart treatment, PP-NRS (Peak Pruritus Numerical Rating Scale) improved by **49.5%** compared to baseline. (Figure C)
- **Stapokibart demonstrated a favorable safety and tolerability profile in the treatment of adolescent AD.**



Kangyueda (康悦达®) | CRSwNP: First in China, Ushering in a New Era of Biologic Therapy

- CRSwNP is a common chronic inflammatory disease of the upper respiratory tract, characterized by severe nasal congestion, anosmia (loss of smell), purulent nasal discharge, and facial pain.
- Stapokibart rapidly alleviates comprehensive nasal symptoms: After 2 weeks of treatment: Nasal polyp size is significantly reduced. After 4 weeks of treatment: Comprehensive nasal symptoms (including nasal congestion, rhinorrhea, and hyposmia or anosmia) show significant improvement.


JAMA®

JAMA | Original Investigation


Stapokibart for Severe Uncontrolled Chronic Rhinosinusitis With Nasal Polyps
The CROWNS-2 Randomized Clinical Trial

日内瓦国际发明展 金奖

1 injection/2W
Quick onset



2 injection/4W
Olfactory recovery



NPS：Nasal Polyp Score；NCS：Nasal Congestion Score；UPSIT：University of Pennsylvania Smell Identification Test；
Significant shrinkage of nasal polyps: ≥1-point improvement in NPS from baseline;
Halving of nasal polyp size: ≥2-point improvement in NPS from baseline;
Improvement in nasal ventilation: ≥0.5-point improvement in weekly NCS from baseline;
Significant improvement in nasal ventilation: ≥1-point improvement in weekly NCS from baseline;
Olfactory recovery: UPSIT score > 18;

Gevaert P et al., Allergy. 2023 Apr;78(4):912-922；Han JK, et at. Lancet Respir Med. 2021 Oct;9(10):1141-1153； Mu Xian et al., Allergy. 2025 Mar 5.；司普奇拜单抗注射液慢性鼻窦炎伴鼻息肉Ⅲ期临床研究报告; Data in file

The above studies represent indirect comparisons; data are not head-to-head.

Kangyueda (康悦达®) | CRSwNP: First in China, Ushering in a New Era of Biologic Therapy


- **All primary endpoints of the Phase III clinical study were met:** At Week 24, 81% of patients achieved ≥50% reduction in nasal polyp size, and 70% achieved significant improvement in nasal congestion.

- At Week 52, **90% of patients achieved ≥50% reduction in nasal polyp volume**. Compared with pivotal Phase III results of similar biologics (dupilumab, mepolizumab, and omalizumab) (where NPS response rates ranged from only 31%–65%) [1-3], Stapokibart demonstrated significantly superior long-term efficacy, setting a new benchmark for biologic treatment of CRSwNP.

- **Stapokibart showed a favorable safety profile :** incidence of TEAEs was comparable to placebo, and no treatment-related SAEs.

12 Injections/24W
Potent Nasal Relief

26 Injections/52W
Durable Clinical Benefit



1. Bachert C, Han JK, Desrosiers M, et al. Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps (LIBERTY NP SINUS-24 and LIBERTY NP SINUS-52): results from two multicentre, randomised, double-blind,placebo-controlled, parallel-group phase 3 trials.Lancet. 2019;394(10209):1638-1650. doi:10.1016/S0140-6736(19)31881-1
2. Han JK, Bachert C, Fokkens W, et al; SYNAPSE Study Investigators. Mepolizumab for chronic rhinosinusitis with nasal polyps (SYNAPSE): a randomised, double-blind, placebo-controlled,phase 3 trial. Lancet Respir Med. 2021;9(10): 1141-1153.doi:10.1016/S2213-2600(21)00097-7
3. Gevaert P, Omachi TA, Corren J, et al. Efficacy and safety of omalizumab in nasal polyposis: 2 randomized phase 3 trials. J Allergy Clin Immunol.2020;146(3):595-605. doi: 10.1016/j.jaci.2020.05.032

Kangyueda (康悦达®) | SAR: The World's Exclusive Solution, Revolutionizing the Treatment Landscape

nature medicine

Article https://doi.org/10.1038/s41591-025-03651-5

Stapokibart for moderate-to-severe seasonal allergic rhinitis: a randomized phase 3 trial

Gold Medal (of the Geneva International Exhibition of Inventions)


The world's only IL-4Rα-targeted antibody drug

The first biological agent with Phase III data in Chinese population

A randomized, double-blind, multicenter, placebo-parallel controlled study that enrolled adult patients with moderate to severe SAR


First injection/Day 2、Week 2 Rapid relief of nasal congestion

rTNSS score improvement was significantly better than the placebo group



Two injections /Week 4 Sustained improvement of rhino-ocular allergy

Stapokibart significantly relieved nasal and ocular allergic symptoms at Week 4



rTNSS: Reflective Total Nasal Symptom Score, including runny nose, nasal congestion, nasal itching and sneezing. Each symptom is scored out of 3 points, with a total score of 12 points.
rTOSS: Reflective Total Ocular Symptom Score, including itchy/burning eyes, lacrimation and conjunctival hyperemia. Each symptom is scored on a scale of 0 to 3 points, with a total score of 9 points.
Mild or no ocular symptoms: The score of each symptom in the daily rTOSS is ≤ 1 point.
Mild or no nasal symptoms: The score of each symptom in the daily rTOSS is ≤ 1 point.

High Tech, High Value

Affordable Innovative Treatment For Everybody!



Scan the QR code to follow the official WeChat account of Kangnuoya

Investor Relations Contact Information: IR@KEYMEDBIO.COM